Exosomes – tiny biological nanoparticles which transfer information between cells – offer significant potential in detecting and treating disease, the most comprehensive overview so far of research in the field has concluded.
Areas which could benefit include cancer treatment and regenerative medicine, say Dr Steven Conlan from Swansea University, Dr Mauro Ferrari of Houston Methodist Research Institute in Texas, and Dr Inês Mendes Pinto from the International Iberian Nanotechnology Laboratory in Portugal. Their commissioned paper, Exosomes as Reconfigurable Therapeutic Systems, is published today by Cell Press in Trends in Molecular Medicine.
Exosomes are particles produced by all cells in the body and are from 30-130 nanometres in size – a nanometre is one-billionth of a metre. They act as biological signalling systems, communicating between cells, carrying proteins, lipids, DNA and RNA. They drive biological processes, from modulating gene expression to transmitting information through breast milk.
Though discovered in 1983, the full potential of exosomes is only gradually being revealed. The researchers show that the nanoparticles’ possible medical benefits fall into three broad categories:
- Detecting disease – by acting as disease-specific biomarkers
- Activating immune responses to boost immunity
- Treating diseases – serving as the vehicle for drugs, for example bearing cancer therapies as their payload, to target tumours
One of the most useful properties of exosomes is that they are able to cross barriers such as the plasma membrane of cells, or the blood/brain barrier. This makes them well-suited to delivering therapeutic molecules in a very targeted way.
The potential benefits of exosomes can be seen in the wide range of research projects – cited in the paper – already either completed or under way, in areas such as:
- Improved testing for prostate cancer
- A small-cell lung cancer trial
- Stem cell-derived exosomes strengthening heart muscles
- Regeneration of muscle and tissue
The team caution that there is more to do before research into exosomes translates into new techniques and treatments. Side-effects need to be considered, and a standardised approach to isolating, characterising and storing exosomes will need to be developed.
Researchers will also need to ensure that the properties of exosomes do not end up causing harm: for example they can transfer drug resistance and pacify the immune system.
Nevertheless, the potential is very clear, with the team describing exosomes as “increasingly promising”.
Professor Steve Conlan of Swansea University Medical School, one of the authors of the paper, said:
“Our survey of research into exosomes shows clearly that they offer enormous potential as a basis for detecting and treating disease.
Further studies are necessary to turn this research into clinical outcomes, but researchers and funders should be very encouraged by our findings. Our own research in Swansea is investigating the use of exosomes and exosome-like synthetic nanoparticles in combatting ovarian and endometrial cancer.
Progress in this field depends on partnership. As the authorship of our own paper illustrates, researchers in different countries are increasingly working together in nanohealth. Swansea University has wider links with Houston and Portuguese based researchers in the field.
It’s also important to build partnerships outside academia, in particular with government and companies in this fast-growing sector.”
The Latest on: Exosomes
- The American Academy of Stem Cell Physicians Sets the Safety Industry Standard in Regenerative Medicineon September 6, 2019 at 5:11 pm
According to AASCP, If you are using biologics in your practice, whether you are using SVF, PRP, bone marrow, UCB, amniotic products, exosomes, xenografts, or peptides, there are key ...
- Creative Diagnostics introduces new lyophilized exosomes for researchon September 6, 2019 at 9:01 am
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics announces that it has developed lyophilized exosomes for global researchers ...
- Capricor Therapeutics to Present at Upcoming Conferenceson September 6, 2019 at 4:30 am
its exosomes program as well as other general corporate updates. A webcast of the Wainwright presentation will be available on Capricor's website at https://capricor.com/news/events/ and will be ...
- Exosomes from Adipose-Derived Stem Cells (ADSCs) Overexpressing miR-21 Promote Vascularization of Endothelial Cellson September 6, 2019 at 3:27 am
In the past few years, exosomes released from adipose-derived stem cells (abbreviated as ADSCs) have shown promises to provide therapeutic benefits in the fields of regenerative medicine. miRNAs, ...
- R3 Stem Cell On The Future Of Stem Cell Therapy Treatmentson September 5, 2019 at 11:27 pm
This includes continuing knowledge regarding the different types of stem cells along with the additional cells that help the body repair itself such as exosomes, secretomes, cytokines, and microRNA.
- Avalon: Poised For Market Conqueston September 5, 2019 at 7:50 pm
They include exosomes diagnostics, regenerative medicine, and cellular immunotherapy. For the diagnostic portfolio, Avalon harnesses the power of "exosomal biomarkers" to launch an avalanche ...
- Protein ‘bubbles’ released from neurons may play role in autismon September 3, 2019 at 9:05 pm
Problems with protein-filled parcels called exosomes contribute to Rett syndrome, a condition related to autism, a new study suggests 1. Exosomes traverse the blood and deliver their cargo by fusing ...
- For Clinical Utility, Exosomes Require New Isolation and Analysis Toolson September 3, 2019 at 4:48 am
Liquid biopsies are widely used for the study of circulating tumor cells and cell-free DNA, but going forward, there will be a very important addition: exosomes. These cargo-carrying extracellular ...
- Emerging role of exosomes as promising diagnostic tool for canceron September 2, 2019 at 3:08 pm
The incidence of cancer is experiencing a steep rise in recent times. A survey report produced by GLOBOCAN 2018 estimates about 18.1 million new cases of cancer across 20 regions of the world. The ...
- Adimarket Set to Share Innovative Exosomes Products at Upcoming Medical Congresseson August 30, 2019 at 12:10 pm
Adimarket, LLC, an online marketplace for regenerative medicine practitioners and a subsidiary of the Global Stem Cells Group (GSCG), has taken to the road in a series of business trips with the ...
via Google News and Bing News